GL1X · GenesisL1 explorer

Research workbench

Human ARTD1 (PARP1) catalytic domain in complex with inhibitor rucaparib

Analyse Human ARTD1 (PARP1) catalytic domain in complex with inhibitor rucaparib in the GL1X research workbench: secondary structure, accessibility, pockets, interfaces, conservation, variants, modifications, peptides, crosslinks and neighbours on the 3D structure.

PDB
4RV6
Type
protein
Length
1,392 residues
Chains
4
Method
x-ray diffraction
Collection
MolNFT v1 / PDB
Contract
0xDE3723766Bc32dcACD03C17BaA400A7B36837Eba
Owner
0x3396CDB397284571d12822B4ae1189a8E22AAAAA
Molecule
Poly [ADP-ribose] polymerase 1
EC
2.4.2.30
UniProt
P09874
Ligands
RPB, SO4
Pockets
17 · best druggability 0.78

Structure

x-ray diffraction · 3 distinct chains · 38% helix, 24% strand (DSSP).

ChainMoleculeTypeResiduesSecondary structureUniProt
APoly [ADP-ribose] polymerase 1 (EC 2.4.2.30)protein34738% helix, 24% strandP09874
B, DPoly [ADP-ribose] polymerase 1 (EC 2.4.2.30)protein34938% helix, 24% strandP09874
CPoly [ADP-ribose] polymerase 1 (EC 2.4.2.30)protein34738% helix, 24% strandP09874

Ligands and binding sites

  • RPB · Rucaparib · ligand · 2 copies · chains A, B
  • SO4 · Sulfate ion · ion · 6 copies · chains A, D, B, C

Binding sites are the residues within 4.5 Å of a ligand's heavy atoms.

Pockets

17 pockets found on a 1 Å grid, 11 with a druggability of 0.5 or more.

PocketVolume (ų)DruggabilityBuriednessLining residuesInside
14350.780.8738empty
23860.780.8838RPB
33850.780.8735empty
43850.770.8740RPB
55110.750.8349SO4

Interfaces

3 interfaces between chains.

  • A–B · 658 Ų buried · 7 hydrogen bonds · protein-protein
  • A–D · 645 Ų buried · 13 hydrogen bonds · protein-protein
  • B–C · 596 Ų buried · 8 hydrogen bonds · protein-protein

Compared structures

  • 4RV6 · Human ARTD1 (PARP1) catalytic domain in complex with inhibitor Rucaparib · the same entry in another collection · chain A against A, TM-score 1.00

Analyse

GL1X is a live explorer of the GenesisL1 blockchain. Turn on JavaScript for search, charts and interactive views.